These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7682157)

  • 1. Antiangiogenic effects of the quinoline-3-carboxamide linomide.
    Vukanovic J; Passaniti A; Hirata T; Traystman RJ; Hartley-Asp B; Isaacs JT
    Cancer Res; 1993 Apr; 53(8):1833-7. PubMed ID: 7682157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers.
    Ichikawa T; Lamb JC; Christensson PI; Hartley-Asp B; Isaacs JT
    Cancer Res; 1992 Jun; 52(11):3022-8. PubMed ID: 1591718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide.
    Vukanovic J; Isaacs JT
    Cancer Res; 1995 Aug; 55(16):3517-20. PubMed ID: 7543015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers.
    Vukanovic J; Isaacs JT
    Cancer Res; 1995 Apr; 55(7):1499-504. PubMed ID: 7533663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
    Joseph IB; Isaacs JT
    Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents.
    Joseph IB; Vukanovic J; Isaacs JT
    Cancer Res; 1996 Aug; 56(15):3404-8. PubMed ID: 8758902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antiangiogenic agent linomide inhibits tumor necrosis factor-alpha secretion via inhibition of its synthesis.
    Joseph IB; Isaacs JT
    Prostate; 1996 Sep; 29(3):183-90. PubMed ID: 8827087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers.
    Vukanovic J; Hartley-Asp B; Isaacs JT
    Prostate; 1995 May; 26(5):235-46. PubMed ID: 7538663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of angiogenesis and metastases of the Lewis-lung cell carcinoma by the quinoline-3-carboxamide, Linomide.
    Borgström P; Torres Filho IP; Hartley-Asp B
    Anticancer Res; 1995; 15(3):719-28. PubMed ID: 7544090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasorelaxant effects induced by the antiangiogenic drug linomide in aortic and saphenous vein preparations of the rabbit.
    Amerini S; Filippi S; Parenti A; Ledda F; Ziche M
    Br J Pharmacol; 1997 Dec; 122(8):1739-45. PubMed ID: 9422822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer.
    Isaacs JT; Pili R; Qian DZ; Dalrymple SL; Garrison JB; Kyprianou N; Björk A; Olsson A; Leanderson T
    Prostate; 2006 Dec; 66(16):1768-78. PubMed ID: 16955399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents.
    Joseph IB; Isaacs JT
    J Natl Cancer Inst; 1998 Nov; 90(21):1648-53. PubMed ID: 9811314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Linomide on adhesion molecules, TNF-alpha, nitrogen oxide, and cell adhesion.
    Abdul-Hai A; Hershkoviz R; Weiss L; Lider O; Slavin S
    Int Immunopharmacol; 2005 Feb; 5(2):231-9. PubMed ID: 15652754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of linomide on the migration and the proliferation of capillary endothelial cells elicited by vascular endothelial growth factor.
    Parenti A; Donnini S; Morbidelli L; Granger HJ; Ziche M
    Br J Pharmacol; 1996 Oct; 119(4):619-21. PubMed ID: 8904633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice.
    Reinmuth N; Liu W; Ahmad SA; Fan F; Stoeltzing O; Parikh AA; Bucana CD; Gallick GE; Nickols MA; Westlin WF; Ellis LM
    Cancer Res; 2003 May; 63(9):2079-87. PubMed ID: 12727823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis.
    Reimer CL; Agata N; Tammam JG; Bamberg M; Dickerson WM; Kamphaus GD; Rook SL; Milhollen M; Fram R; Kalluri R; Kufe D; Kharbanda S
    Cancer Res; 2002 Feb; 62(3):789-95. PubMed ID: 11830534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
    Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
    Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linomide improves the effect of interstitial laser thermotherapy in a rat liver tumour model.
    Ivarsson K; Sturesson C; Stenram U; Tranberg KG
    Anticancer Res; 2003; 23(2B):1257-63. PubMed ID: 12820380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antiangiogenic agent linomide inhibits the growth rate of von Hippel-Lindau paraganglioma xenografts to mice.
    Gross DJ; Reibstein I; Weiss L; Slavin S; Stein I; Neeman M; Abramovitch R; Benjamin LE
    Clin Cancer Res; 1999 Nov; 5(11):3669-75. PubMed ID: 10589785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.